Beclometasone dipropionate was first patented in 1962 and used medically in 1972.  It was approved for medical use in the United States in 1976.  It is on the World Health Organization's List of Essential Medicines , the most effective and safe medicines needed in a health system .  The wholesale price in the developing world for an inhaler containing 200 doses of medication is about USD as of 2014.  In the United States it costs between 50 and 100 USD for a typical month supply of the inhaled form. 
QNASL Nasal Aerosol is a pressurized, nonaqueous solution in a metered-dose aerosol device intended ONLY for intranasal use. It contains a solution of beclomethasone dipropionate in propellant HFA-134a (1,1,1,2-tetrafluoroethane) and dehydrated ethanol. QNASL 40 mcg Nasal Aerosol delivers 40 mcg of beclomethasone dipropionate from the nasal actuator and 50 mcg from the valve. QNASL 80 mcg Nasal Aerosol delivers 80 mcg of beclomethasone dipropionate from the nasal actuator and 100 mcg from the valve. Each strength delivers 59 mg of solution from the valve with each actuation. Each canister of QNASL 40 mcg or 80 mcg Nasal Aerosol, contains g of drug and excipients and each provides 120 actuations after priming. Additionally, QNASL 40 mcg Nasal Aerosol contains g of drug and excipients and provides 60 actuations after priming.